Transthyretin amyloidosis
2 papers
- Humans2
Trial sponsors
Peking University Third Hospital
1 trialPhase 410 people
1 trialPhase 255 people
Funding
2 grants since 2020National Heart, Lung, and Blood InstituteUS$809.3kNational Institute of Diabetes and Digestive and Kidney DiseasesUS$566.6k
Am I ATTRisk? Health empowerment through population genomic screening for transthyretin amyloidosis
National Heart, Lung, and Blood InstituteIcahn School of Medicine at Mount SinaiUS$809.3k2026–2031
Molecular mechanisms of transthyretin amyloidosis
National Institute of Diabetes and Digestive and Kidney DiseasesScripps Research Institute, theUS$566.6k2020–2028
Latest
4 in 12 monthsCardiology and Therapy
Neurologic Stability During Tafamidis Treatment in Transthyretin Amyloidosis with a Mixed Phenotype: A Multicenter Real-World Study
Cohort study of 67 peopleInterventions
Cardiology and Therapy
Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy
Cohort study of 1,924 peopleInterventions
The Journal of Hand Surgery, European Volume
Screening for amyloidosis in trigger finger release and Dupuytren's fasciectomy
Cohort study in peopleCardiac amyloidosis
AHA Scientific Sessions 2025 Abstract
High Prevalence and Adverse Cardiovascular Outcomes of the Transthyretin p.Asp119Asn Variant in Japan
Study in peoplePopulations